Last reviewed · How we verify
ciclesonide nasal aerosol
Ciclesonide is an inhaled corticosteroid that reduces inflammation in the nasal airways by binding to glucocorticoid receptors and suppressing inflammatory mediator production.
Ciclesonide is an inhaled corticosteroid that reduces inflammation in the nasal airways by binding to glucocorticoid receptors and suppressing inflammatory mediator production. Used for Allergic rhinitis, Nasal polyps (in some formulations/regions).
At a glance
| Generic name | ciclesonide nasal aerosol |
|---|---|
| Also known as | Zetonna |
| Sponsor | Sumitomo Pharma America, Inc. |
| Drug class | Intranasal corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Allergy/Immunology |
| Phase | FDA-approved |
Mechanism of action
Ciclesonide is a prodrug that is converted to its active metabolite in the nasal tissue, where it binds to glucocorticoid receptors in the cytoplasm. This binding translocates the receptor to the nucleus, where it modulates gene transcription to decrease production of inflammatory cytokines, chemokines, and adhesion molecules. The result is reduced nasal inflammation, congestion, and allergic symptoms.
Approved indications
- Allergic rhinitis
- Nasal polyps (in some formulations/regions)
Common side effects
- Headache
- Epistaxis (nosebleed)
- Nasal irritation
- Pharyngitis
Key clinical trials
- PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V (PHASE2, PHASE3)
- Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422) (PHASE4)
- Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis (PHASE4)
- Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia (PHASE3)
- Efficacy, Safety & Tolerability of Ciclesonide 200mcg Spray 4 Weeks Treatment for Intermittent & Persistent Rhinitis
- Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409) (PHASE3)
- Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602) (PHASE2)
- Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ciclesonide nasal aerosol CI brief — competitive landscape report
- ciclesonide nasal aerosol updates RSS · CI watch RSS
- Sumitomo Pharma America, Inc. portfolio CI